Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.VA106483, a novel small molecule drug candidate that exerts effect directly in kidney by binding to vasopressin receptors
Subscribe to our email newsletter
The trial showed that oral VA106483 was successful in producing a predictable and sustained anti-diuretic effect in nocturia patients, as determined by increased osmolality and decreased urine output.
VA106483 is a novel small molecule drug candidate, that exerts its effect directly in the kidney by binding to vasopressin receptors.
The double-blind, placebo-controlled, dose-response study was designed to investigate the pharmacodynamics and pharmacokinetics of single and repeated oral doses of VA106483. The trial involved 27 elderly men aged 65 years or more with nocturia.
The study reportedly found that VA106483 was generally well tolerated among the patients.
Dr. Jim Phillips, CEO of Vantia, said: The clinical results for VA106483 are very encouraging and we look forward to advancing it into the next stages of clinical development. These results will also further highlight the value of this new drug candidate as we progress partnership discussions in parallel.